OneMedNet Signs Global Pharmaceutical Intelligence Provider as Channel Partner, Extending Reach in Pharma Market

Agreement with a leading global provider of pharmaceutical intelligence and data solutions expands distribution of OneMedNet’s first-party, direct-from-source multimodal Real-World Data; Strengthening its presence in a rapidly growing pharmaceutical data market

MINNEAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced its 12th channel partner agreement, under which a leading global provider of pharmaceutical intelligence and data solutions will distribute OneMedNet’s U.S.-sourced, de-identified clinical data to its established base of pharmaceutical customers worldwide. The agreement broadens OneMedNet’s reach into one of the fastest-growing segments of life sciences data. The global Real-World Data market is estimated at approximately US$2.7 billion in 2026 and is projected to reach US$7.1 billion by 2033, according to Coherent Market Insights¹, as pharmaceutical companies increasingly rely on Real-World Data to support drug development, regulatory submissions, and commercial decisions.

OneMedNet is witnessing data partners increasingly select its Real-World Data for the qualities pharmaceutical customers value most: first-party data sourced directly from healthcare providers rather than intermediaries or secondary markets, de-identified at the source, and delivered at regulatory-grade quality. By pairing OneMedNet’s multimodal clinical data with their own analytics and intelligence offerings, partners can support their pharmaceutical customers across clinical development, regulatory submissions, market access, and medical AI.

This agreement marks OneMedNet’s 12th channel partnership, reflecting a deliberate strategy to extend the Company’s commercial reach through established distribution channels while maintaining direct control of data sourcing, curation, and de-identification.

“We believe our channel partners choose OneMedNet for the same reason end customers do: data that comes straight from the source,” said Aaron Green, President & CEO of OneMedNet. “First-party, direct-from-source data gives our partners confidence in the quality, provenance, and compliance of what they deliver to their customers. This partnership expands our reach in the pharmaceutical market.”

About OneMedNet Corporation

OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.

Learn more at www.onemednet.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the benefits and expected scope of the channel partner agreement, our distribution strategy, and statements generally about our products, plans and strategies.

Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

OneMedNet Contacts:

Michael Wong, VP Marketing

Email: michael.wong@onemednet.com

SOURCE: ONEMEDNET CORPORATION

1. https://www.coherentmarketinsights.com/market-insight/real-world-data-rwd-market-6029